Glucagonoma Syndrome: A Case Report
Keywords:
Glucagonoma syndromes, necrolytic migratory erythema (NME), glucagon, somatostatinAbstract
A 58-year-old Malay female with underlying diabetes mellitus, presented with chronic skin lesions, associated with weight loss and anemia. There were erosive, scaling skin lesions over the extremities, gluteal region and perioral area. Skin biopsy histopathological examination revealed Necrolytic Migratory Erythema (NME). A CT scan of the abdomen revealed a pancreatic neck and body tumor with possible liver metastases. She was successfully treated with subcutaneous somatostatin and underwent distal pancreatectomy with wedge resection of liver nodule.
Downloads
References
Sachithanandan S, Tzen CY, Raman K, Colao A. Neuroendocrine tumor symposium (GIST & NETs: A Multidisciplinary Journey). Oncology Tribune. Nov. 2010:2. http://www.mems.my/file_dir/20344153334d6c5f4d5d075.pdf.
Alkemade JA, van Tongeren JH, van Haelst UJ, et al. Delayed diagnosis of glucagonoma syndrome. Clin Exp Dermatol. 1999;24(6):455-7. http://dx.doi.org/10.1046/j.1365-2230.1999.00531.x.
Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV. The glucagonoma syndrome: Clinical and pathologic features in 21 patients. Medicine (Baltimore).1996;75(2):53-63. http://dx.doi.org/10.1097/00005792-199603000-00002.
DeLellis RA , ed. Pathology and genetics of tumours of endocrine organs, 3rd ed. Vol. 8. IARC WHO Classification of tumours, 2004.
Butte JM, Montero PH, Solar A, Torres J, et al. Cervical metastases of glucagonoma in a patient with multiple endocrine neoplasia type 1: Report of a case. Surgery Today. 2008;38(12):1137-43. http://dx.doi.org/10.1007/s00595-008-3763-1.
Eldor R, Glaser B, Fraenkel M, Doviner V, et al. Glucagonoma and the glucagonoma syndrome–cumulative experience with an elusive endocrine tumour. Clin Endocrinol. 2011;74(5):593-98. http://dx.doi.org/10.1111/j.1365-2265.2011.03967.x.
Shi W, Liao W, Mei X, Xiao Q, et al. Necrolytic migratory erythema associated with glucagonoma syndrome. J Clin Oncol. 2010; 28(20):e329-e331. http://dx.doi.org/10.1200/JCO.2009.25.7113.
Stacpoole PW. The glucagonoma syndrome: Clinical features, diagnosis, and treatment. Endocr Rev. 1981; 2(3):347-61. http://dx.doi.org/ http://dx.doi.org/10.1210/edrv-2-3-347.
Koike N, Hatori T, Imaizumi T, Harada N, et al. Malignant glucagonoma of the pancreas diagnosed through anemia and diabetes mellitus. J Hepatobiliary Pancreat Surg. 2003:10(1):101-5. http://dx.doi.org/ 10.1007/s10534-002-0791-y.
Fenkci SM, Yaylali GF, Sermez Y, Akdam H, et al. Malign cystic glucagonoma presented with diabetic ketoacidosis: Case report with an update. Endocr Relat Cancer. 2005; 12(2):449-54. http://dx.doi.org/ 10.1677/erc.1.00957.
McGevna L, McFadden D, Ritvo J, et al. Glucagonoma-associated neuropsychiatric and affective symptoms: Diagnostic dilemmas raised by paraneoplastic phenomena. Psychosomatics. 2009;50(5):548-9. http://dx.doi.org/ 10.1176/appi.psy.50.5.548.
Mallinson CN, Bloom SR, Warin AP, Salmon PR, Cox B. A glucagonoma syndrome. The Lancet.1974; 304(7871): 1-5. http://dx.doi.org/10.1016/S0140-6736(74)91343-9.
van Beek AP, de Haas ER, van Vloten WA, et al. The glucagonoma syndrome and necrolytic migratory erythema: A clinical review. Eur J Endocrinol. 2004:151(5):531-7. http://dx.doi.org/10.1530/eje.0.1510531.
Remes‐Troche JM, García-de-Acevedo B, Zuñiga-Varga J, et al. Necrolytic migratory erythema: A cutaneous clue to glucagonoma syndrome. J Eur Acad Dermatol Venereol. 2004;18(5):591-5. http://dx.doi.org/ 10.1111/j.1468-3083.2004.00981.x.
Teixeira RC, Nico MM, Ghideti AC. Necrolytic migratory erythema associated with glucagonoma: A report of 2 cases. Clinics. 2008:63(2):267-70. http://dx.doi.org/10.1590/S1807-59322008000200016.
Kitamura Y, Sato M, Hatamochi A, Yamazaki S, et al. Necrolytic migratory erythema without glucagonoma associated with hepatitis B. Eur J Dermatol. 2005;15(1):49-51.
Delaporte E, Catteau B, Piette F. Necrolytic migratory erythema‐like eruption in zinc deficiency associated with alcoholic liver disease. Br J Dermatol.1997;137(6):1027-8. http://dx.doi.org/10.1111/j.1365-2133.1997.tb01583.x.
Castro PG, de León AM, Trancón JG, et al. Glucagonoma syndrome: A case report. J Med Case Rep .2011;5:402. http://dx.doi.org/10.1186/1752-1947-5-402.
O’Grady HL, Conlon KC. Pancreatic neuroendocrine tumours. Eur J Surg Oncol. 2008;34(3):324–32. http://dx.doi.org/10.1016/j.ejso.2007.07.209.
Kindmark H, Sundin A, Granberg D, Dunder K, Skogseid B, Janson ET. Endocrine pancreatic tumors with glucagon hypersecretion: A retrospective study of 23 cases during 20 years. Medical Oncology. 2007;24(3):330-7. http://dx.doi.org/10.1007/s12032-007-0011-2.
Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. New Engl J Med. 2003;348(25): 2579-80. http://dx.doi.org/10.1056/NEJM200306193482519.
Chastain MA. The glucagonoma syndrome: A review of its features and discussion of new perspectives. Am J Med Sci. 2001;321(5):306-20. http://dx.doi.org/ 10.1097/00000441-200105000-00003.
Norton J, Kivlen M, Li M, Schneider D, et al. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg. 2003;138(8):859-66. http://dx.doi.org/10.1001/archsurg.138.8.859.
Stabile BE. Islet cell tumors. The Gastroenterologist.1997;5(3):213-32.
Kheir SM, Omura EF, Grizzle W. Histologic variation in the skin lesions of the glucagonoma syndrome. Am J Surg Pathol. 1986;10(7):445-53.
Boden G. Insulinoma and glucagonoma. Semin Oncol. 1987;14(3):253-62.
El Darouty M, El Ela MA. Necrolytic migratory erythema without glucagonoma in patients with liver disease. J Am Acad Dermatol. 1996;34(6):1092. http://dx.doi.org/10.1016/S0190-9622(96)90299-6.
Chu QD, Al-kasspooles MF, Smith JL, et al. Is glucagonoma of the pancreas a curable disease? Int J Pancreatol. 2001;29(3):155-62. http://dx.doi.org/ 10.1385/IJGC:29:3:155.
Liu WJ, Zhao YP, Zhang TP, Liao Q, Cong L. Clinical experience in diagnosis and treatment of glucagonoma. Zhonghua wai ke za zhi. Chinese. 2009;47(5): 333-6.
Åkerström G, Hellman P, Hessman O, Osmak L. Surgical treatment of endocrine pancreatic tumours. Neuroendocrinology. 2004;80(Suppl. 1):62-6. http://dx.doi.org/10.1159/000080744.
Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656-63. http://dx.doi.org/10.1200/JCO.2009.22.8510.
Alexander EK, Robinson M, Staniec M, Dluhy RG. Peripheral amino acid and fatty acid infusion for the treatment of necrolytic migratory erythema in the glucagonoma syndrome. Clin Endocrinol. 2002;57(6):827-31. http://dx.doi.org/10.1046/j.1365-2265.2002.01660.x.
Kulke MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Choti MA, et al. Neuroendocrine tumors. J Natl Compr Canc Netw. 201;10(6):724-64.
Published
How to Cite
Issue
Section
License
Journal of the ASEAN Federation of Endocrine Societies is licensed under a Creative Commons Attribution-NonCommercial 4.0 International. (full license at this link: http://creativecommons.org/licenses/by-nc/3.0/legalcode).
To obtain permission to translate/reproduce or download articles or use images FOR COMMERCIAL REUSE/BUSINESS PURPOSES from the Journal of the ASEAN Federation of Endocrine Societies, kindly fill in the Permission Request for Use of Copyrighted Material and return as PDF file to jafes@asia.com or jafes.editor@gmail.com.
A written agreement shall be emailed to the requester should permission be granted.
